Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 10/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | HTR1D | P28221 | 2/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.51 |
| ▸ | OGG1 | O15527 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10458226 | 0.83 | HTR1B (0.72) | HTR1BKDM4EALDH1A1HPGDKCNA3 | |
| SCHEMBL16902842 | 0.82 | HTR1B (0.64) | HTR1BKDM4EALDH1A1HPGDKCNA3 | |
| SCHEMBL5289923 | 0.82 | HTR1B (0.77) | HTR1BKDM4EALDH1A1HPGDKCNA3 | |
| SCHEMBL7682354 | 0.81 | DRD1 (0.50) | KDM4EALDH1A1HPGDTDP1CYP1A2 | |
| SCHEMBL9770352 | 0.80 | KCNA3 (0.81) | HTR1BKCNA3TDP1HTR1DSLC6A4 | |
| SCHEMBL2177350 | 0.80 | HTR1B (0.78) | HTR1BKCNA3TDP1HTR1DSLC6A4 | |
| SCHEMBL6675778 | 0.80 | HTR1B (0.62) | HTR1BKDM4EALDH1A1HPGDKCNA3 | |
| SCHEMBL12154321 | 0.79 | MAPT (0.57) | HTR1BKDM4EALDH1A1HPGDKCNA3 | |
| SCHEMBL10698527 | 0.78 | HTR1B (0.60) | HTR1BKDM4EALDH1A1HPGDKCNA3 | |
| SCHEMBL16902855 | 0.78 | KCNA3 (0.79) | HTR1BKCNA3TDP1HTR1DSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10974235-B2 | Targeted, metal-catalyzed fluorination of complex compounds with fluoride ion via decarboxylation | TRUSTEES OF PRINCETON UNIVERSITY (US) | 2021-04-13 | — | — | US | disclosed |
| US-10543481-B2 | Targeted, metal-catalyzed fluorination of complex compounds with fluoride ion via decarboxylation | TRUSTEES OF PRINCETON UNIVESITY (US) | 2020-01-28 | — | — | US | disclosed |
| CN-105593217-B | Terazololine-one compound and application thereof | 住友化学株式会社 | 2018-05-25 | — | — | CN | disclosed |
| US-20180037526-A1 | TARGETED, METAL-CATALYZED FLUORINATION OF COMPLEX COMPOUNDS WITH FLUORIDE ION VIA DECARBOXYLATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180037526-A1 | TARGETED, METAL-CATALYZED FLUORINATION OF COMPLEX COMPOUNDS WITH FLUORIDE ION VIA DECARBOXYLATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2018-02-08 | — | — | US | disclosed |
| WO-2016130549-A1 | TARGETED, METAL-CATALYZED FLUORINATION OF COMPLEX COMPOUNDS WITH FLUORIDE ION VIA DECARBOXYLATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2016-08-18 | — | — | WO | disclosed |
| US-20160158388-A1 | TARGETED, METAL-CATALYZED FLUORINATION OF COMPLEX COMPOUNDS WITH FLUORIDE ION VIA DECARBOXYLATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160158388-A1 | TARGETED, METAL-CATALYZED FLUORINATION OF COMPLEX COMPOUNDS WITH FLUORIDE ION VIA DECARBOXYLATION | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2016-06-09 | — | — | US | disclosed |
| EP-1836158-B1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158388-A1 | TARGETED, METAL-CATALYZED FLUORINATION OF COMPLEX COMPOUNDS WITH FLUORIDE ION VIA DECARBOXYLATION | AFF2, CLTC, AFF4 | HTR1B 3216/4885KDM4E 1877/4885ALDH1A1 2126/4885 |
| US-10543481-B2 | Targeted, metal-catalyzed fluorination of complex compounds with fluoride ion via decarboxylation | AFF2, CLTC, AFF4 | HTR1B 3216/4885KDM4E 1877/4885ALDH1A1 2126/4885 |
| US-20180037526-A1 | TARGETED, METAL-CATALYZED FLUORINATION OF COMPLEX COMPOUNDS WITH FLUORIDE ION VIA DECARBOXYLATION | AFF2, CLTC, AFF4 | HTR1B 3216/4885KDM4E 1877/4885ALDH1A1 2126/4885 |
| US-10974235-B2 | Targeted, metal-catalyzed fluorination of complex compounds with fluoride ion via decarboxylation | AFF2, CLTC, AFF4 | HTR1B 3216/4885KDM4E 1877/4885ALDH1A1 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.